Drug intelligence / Profile preview

YB-1113

Development stage: Phase 1
Lead developer: Bright Cell
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

YB-1113 is an investigational allogeneic cell therapy composed of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). Developed by the South Korean biotechnology company Bright Cell, Inc., YB-1113 is currently in Phase 1 clinical development for the treatment of premature ovarian insufficiency (POI). The therapy is administered via intravenous infusion and is designed to restore ovarian function by leveraging the regenerative and immunomodulatory properties of mesenchymal stem cells. These cells are hypothesized to migrate to damaged ovarian tissue and release paracrine factors, such as cytokines and growth factors, that promote tissue repair, inhibit granulosa cell apoptosis, and modulate the local immune environment to support follicular development and hormonal balance.

Other names: human umbilical cord-derived mesenchymal stem cellshUC-MSCs

Beyond the preview

Go deeper on YB-1113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YB-1113.

Explore the full profile